Business Context and Reporting Period
Company: Intensity Therapeutics, Inc. (INTS)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended March 31, 2026
Business Overview: A late-stage clinical biotechnology company developing INT230-6, an intratumoral cancer treatment using the DfuseRx platform. The company has no product revenue and relies on equity financing.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,434) | $(3,347) |
| Loss Per Share (Basic & Diluted) | $(0.96) | $(5.51) |
| Operating Expenses | $2,526 | $3,394 |
| Cash and Cash Equivalents (End of Period) | $10,245 | $929 |
| Net Cash Used in Operating Activities | $(1,826) | $(1,989) |
| Accumulated Deficit | $(80,823) | $(70,130) |
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $868,000 (26%) primarily due to a $1.1 million reduction in clinical trial costs for the INVINCIBLE-3 Study (Phase 3 Sarcoma), which was paused in March 2025 due to funding constraints.
- Improved Loss Position: Net loss narrowed by $913,000 (27%) compared to Q1 2025, driven by lower R&D spend and higher interest income ($94,000 vs. $15,000).
- Capital Structure: The company executed a 1-for-25 reverse stock split on February 19, 2026. All prior period share data has been restated.
- Liquidity: Cash balances increased significantly from $929,000 in Q1 2025 to $10.2 million in Q1 2026, bolstered by equity offerings in 2025 and early 2026.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management states there is "substantial doubt" about the company's ability to continue as a going concern. Operations are dependent on obtaining additional capital, which is not within the company's control.
- Clinical Trial Status:
- INVINCIBLE-3 (Phase 3 Sarcoma): Enrollment paused in March 2025. Management plans to resume limited enrollment in Q3 2026 pending funding.
- INVINCIBLE-4 (Phase 2 Breast): Enrollment paused in September 2025 to revise dosing. Preliminary data showed 71% pathological complete response (pCR) in the treatment cohort. Enrollment resumed in Q2 2026 following protocol approval.
- Financing Activities: The company raised funds via an At-The-Market (ATM) offering (increased cap to $60 million in March 2026) and completed public offerings in April, June, and October 2025. Subsequent to quarter-end, an additional $0.6 million was raised via ATM.
- Risks: Key risks include the inability to raise further capital, delays in clinical trials, and potential impacts on patents held in Russia and Israel due to military actions.
Investor Verification Checklist
- Cash Runway: Verify the projected burn rate against the $10.2 million cash balance to determine the timeline for the next capital raise.
- ATM Capacity: Confirm the remaining capacity under the $60 million ATM agreement and recent sales velocity.
- Clinical Resumption: Monitor the actual resumption of patient enrollment in the INVINCIBLE-3 and INVINCIBLE-4 studies as planned for Q2/Q3 2026.
- Reverse Split Impact: Review the impact of the 1-for-25 reverse split on share liquidity and Nasdaq listing compliance.
- Related Party Transactions: Note the $38,260 expense and $15,022 payable to a service organization controlled by a board member.